Xencor, Inc.
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
Last updated:
Abstract:
The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
Status:
Grant
Type:
Utility
Filling date:
8 Nov 2018
Issue date:
26 Apr 2022